Chirurgische Behandlung von peritoneal disseminierten gastrointestinalen Tumoren

Zusammenfassung

Die Peritonealkarzinose gastrointestinaler Malignome ist mit einer schlechten Prognose verbunden. Bis zu 15 % der Patienten mit kolorektalen Karzinomen erleiden im Verlauf der Erkrankung eine Peritonealkarzinose. Dieser Prozentsatz liegt bei Patienten mit Magenkarzinom höher. In den letzten Jahren konnte durch eine zytoreduktive Chirurgie, bestehend aus einer parietalen und viszeralen Peritonektomie in Kombination mit einer hyperthermen intraperitonealen Chemotherapie, eine 5-Jahres-Überlebensrate von 30 - 40 % für peritoneal metastasierte kolorektale Karzinome erreicht werden. Dieses konnte durch eine prospektiv, randomisierte Studie sowie mehrere Phase-II-Studien belegt werden. Wichtig ist eine sorgfältige Auswahl der Patienten und das Erreichen einer kompletten makroskopischen Zytoreduktion. Weniger erfolgreich war bisher die Durchführung des Konzeptes beim Magenkarzinom mit Peritonealkarzinose, wobei hier der adjuvante Ansatz nach Gastrektomie ohne Peritonealkarzinose attraktiver erscheint. Für Patienten mit Karzinomen der Leber, Gallenwege und Pankreas kommt das Konzept nicht infrage. Um die Patienten, bei denen eine Prognoseverbesserung durch die Therapie möglich ist, besser identifizieren zu können, sind weitere prospektive, randomisierte Studien zur Rolle der hyperthermen intraperitonealen Chemotherapie notwendig. Diese müssen interdisziplinär und multizentrisch mit der Unterstützung der zuständigen Fachgesellschaften geplant werden.

Abstract

Peritoneal carcinomatosis is found in approximately 15 % of patients with colorectal cancer during the course of their disease, and is associated with a poor prognosis. Even more patients with gastric cancer develop peritoneal seeding. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) have been introduced in the past decade and have led to 5-year survival rates of 30 to 40 % for selected patients with colorectal cancer and peritoneal carcinomatosis. These numbers have been demonstrated by many retrospective analyses and by prospective Phase II studies. The clinical assessment to select patients who will benefit from the combined therapy and achievement of complete macroscopic cytoreduction both play a crucial role. Less favourabale results have been achieved for patients suffering from stage IV gastric cancer with peritoneal seeding. Promising results were demonstrated for postoperative intraperitoneal chemotherapy following curative gastrectomy. Patients with hepatic, biliary and pancreatic cancers and peritoneal carcinomatosis do not benefit from cytoreductive surgery. There is a need for further multicentre, prospective trials analysing the use of hyperthermic intraperitoneal chemotherapy. They should be conducted in the specialised centres by interdisciplinary teams.

Magenkarzinom - Peritonektomie - kolorektales Karzinom - Peritonealkarzinose - Pseudomyxoma

peritonectomy - peritoneal carcinomatosis - colorectal cancer - gastric cancer - pseudomyoxoma

Literatur

• 1 Sadeghi B, Arvieux C, Glehen O. et al . Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.  Cancer. 2000;  88 358-363
• 2 Hinson F L, Ambrose N S. Pseudomyxoma peritonei.  Br J Surg. 1998;  85 1332-1339
• 3 Sugarbaker P H, Ronnett B M, Archer A. et al . Pseudomyxoma peritonei syndrome.  Adv Surg. 1996;  30 233-280
• 4 Moran B J, Cecil T D. The etiology, clinical presentation, and management of pseudomyxoma peritonei.  Surg Oncol Clin N Am. 2003;  12 585-603
• 5 Miner T J, Shia J, Jaques D P. et al . Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy.  Ann Surg. 2005;  241 300-308
• 6 Esquivel J, Sugarbaker P H. Clinical presentation of the Pseudomyxoma peritonei syndrome.  Br J Surg. 2000;  87 1414-1418
• 7 Sugarbaker P H. Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy.  Oncology (Williston-Park). 2004;  18 207-219
• 8 Ronnett B M, Zahn C M, Kurman R J. et al . Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to „pseudomyxoma peritonei”.  Am J Surg Pathol. 1995;  19 1390-1408
• 9 Sugarbaker P H. Cytoreduction including total gastrectomy for pseudomyxoma peritonei.  Br J Surg. 2002;  89 208-212
• 10 Elias D, Raynard B, Boige V. et al . Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.  J Surg Oncol. 2005;  90 220-225
• 11 Schmidt U, Dahlke M H, Klempnauer J. et al . Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.  Eur J Surg Oncol. 2005;  31 53-58
• 12 Piso P, Bektas H, Werner U. et al . Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma.  Eur J Surg Oncol. 2001;  27 286-290
• 13 Ceelen W P, Hesse U, Hemptinne B de. et al . Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer.  Br J Surg. 2000;  87 1006-1015
• 14 Verwaal V J, Ruth S van, Bree E R. et al . Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.  J Clin Oncol. 2003;  21 3737-3743
• 15 Verwaal V J, Tinteren H de, Ruth S V van. et al . Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.  J Surg Oncol. 2004;  85 61-67
• 16 Bryant J, Clegg A J, Sidhu M K. et al . Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei.  Br J Surg. 2005;  92 153-158
• 17 Esquivel J, Sugarbaker P H. Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients.  Ann Surg. 2001;  234 198-205
• 18 Sugarbaker P H. Are there curative options to peritoneal carcinomatosis?.  Ann Surg. 2005;  242 748-750
• 19 Stamou K M, Karakozis S, Sugarbaker P H. Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer.  J Surg Oncol. 2003;  83 197-203
• 20 Shen P, Hawksworth J, Lovato J. et al . Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.  Ann Surg Oncol. 2004;  11 178-186
• 21 McQuellon R P, Loggie B W, Lehman A B. et al . Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.  Ann Surg Oncol. 2003;  10 155-162
• 22 Esquivel J, Farinetti A, Sugarbaker P H. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed.  G Chir. 1999;  20 81-86
• 23 Jayne D G, Fook S, Loi C. et al . Peritoneal carcinomatosis from colorectal cancer.  Br J Surg. 2002;  89 1545-1550
• 24 Glehen O, Cotte E, Schreiber V. et al . Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin.  Br J Surg. 2004;  91 747-754
• 25 Pestieau S R, Sugarbaker P H. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.  Dis Colon Rectum. 2000;  43 1341-1346
• 26 Chu D Z, Lang N P, Thompson C. et al . Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors.  Cancer. 1989;  63 (2) 364-367
• 27 Verwaal V J, Ruth S van, Witkamp A. et al . Long-term survival of peritoneal carcinomatosis of colorectal origin.  Ann Surg Oncol. 2005;  12 65-71
• 28 Glehen O, Kwiatkowski F, Sugarbaker P H. et al . Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.  J Clin Oncol. 2004;  22 3284-3292
• 29 Elias D, Delperro J R, Sideris L. et al . Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials.  Ann Surg Oncol. 2004;  11 518-521
• 30 Jacquet P, Stuart O A, Dalton R. et al . Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites.  J Surg Oncol. 1996;  62 128-134
• 31 Verwaal V J, Tinteren H van, van-Ruth S. et al . Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy.  Br J Surg. 2004;  91 739-746
• 32 Yu W, Whang I, Suh I. et al . Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer.  Ann Surg. 1998;  228 347-354
• 33 Koga S, Hamazoe R, Maeta M. et al . Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C.  Cancer. 1988;  61 232-237
• 34 Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.  Cancer. 1994;  73 2048-2052
• 35 Fujimura T, Yonemura Y, Muraoka K. et al . Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study.  World J Surg. 1994;  18 150-155
• 36 Yonemura Y, Ninomiya I, Kaji M. et al . Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer.  World J Surg. 1995;  19 450-454
• 37 Ikeguchi M, Kondou A, Oka A. et al . Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion.  Eur J Surg. 1995;  161 581-586
• 38 Fujimoto S, Takahashi M, Mutou T. et al . Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma.  Cancer. 1999;  85 529-534
• 39 Kim J Y, Rhew C H, Kim K S. et al . Controlled clinical trial for the gastric carcinoma patients who underwent surgery plus IHCP. Proceedings of the Third International Gastric Cancer Congress 1999, Seoul, Korea.  1999;  106
• 40 Sugarbaker P H, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer.  Semin Surg Oncol. 2003;  21 233-248
• 41 Samel S, Singal A, Becker H. et al . Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer.  Eur J Surg Oncol. 2000;  26 222-226
• 42 Hagiwara A, Sawai K, Sakakura C. et al . Complete omentectomy and extensive lymphadenectomy with gastrectomy improves the survival of gastric cancer patients with metastases in the adjacent peritoneum.  Hepatogastroenterology. 1998;  45 1922-1929
• 43 Fujimoto S, Shrestha R D, Kokubun M. et al . Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding.  Ann Surg. 1988;  208 36-41
• 44 Hirose K, Katayama K, Iida A. et al . Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis.  Oncology. 1999;  57 106-114
• 45 Yonemura Y, Kawamura T, Bandou E. et al . Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion.  Br J Surg. 2005;  92 370-375
• 46 Fujimura T, Yonemura Y, Fushida S. et al . Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation.  Cancer. 1990;  65 65-71
• 47 Brigand C, Arvieux C, Gilly F N. et al . Treatment of peritoneal carcinomatosis in gastric cancers.  Dig Dis. 2004;  22 366-373